Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Combined Highly Active Anti-retroviral Microbicides (CHAARM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,France,Belgium,United Kingdom,Switzerland,Italy,Belgium,United Kingdom,Netherlands,Spain,Spain,South Africa,Belgium,Netherlands,Austria,United States,Sweden,Belgium,Ukraine,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-06-30
Duration (months): 66.0
Total project cost (EUR): 17067499.59
EU funding (EUR): 11999998.4
Participants: 34
Project status: CLOSED

This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of resistance. The proposal includes development of both slow release and gel formulations, pharmacokinetic and challenge experiments in macaques as well as human studies including a collaborative study with an EDCTP-funded project to use multiplex and proteomic technologies as well as culture-independent DNA-based analysis of mucosal microbiota to investigate biomarkers and establish a baseline signature from which perturbations can be recognised. This is a large consortium comprising 30 partners from 8 EU countries and from Switzerland, Ukraine, South Africa and the United States.Partners include microbicide developers, IPM and Particle Sciences, and producers, Gilead, Tibotec and Virco. Two SMEs will also participate in RTD aspects. The consortium is multidisciplinary with scientists engaged in basic discovery working with new targets and developing novel chemistry to produce compounds with improved safety and efficacy profiles as well as altered patterns of resistance.

Keywords: hiv-1 microbicides,nnrti,integrase inhibitors,fusion inhibitors,formulation,intra-vaginal ring,clinical trial,biomarkers,proteomics,hiv in vitro testing,ccr5 inhibitors,rantes analogues
European multicenter network to evaluate pharmacokinetics, safety and efficacy of Meropenem in neonatal sepsis and meningitis (NEOMERO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Italy,United Kingdom,France,Estonia,Netherlands,Greece,Spain,Italy,Lithuania,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-06-30
Duration (months): 66.0
Total project cost (EUR): 7672901.94
EU funding (EUR): 5900000.0
Participants: 12
Project status: CLOSED

Previous studies have demonstrated the high frequency of bacterial sepsis in neonates and infants admitted to neonatal intensive care unit (NICU), often associated with serious complications or death. Many pathogens capable of causing nosocomial bacterial sepsis in neonates and young infants have developed resistance to the antibiotics considered of choice for treatment. Meropenem is an antibiotic that can overcome antimicrobial resistance, generally being safe and well tolerated with very good pharmacokinetic (PK) and pharmacodynamic characteristics. However, it has not yet been registered in neonates and infants aged &lt;3 months due to limited data on its PK characteristics, activity and safety. Core objectives of NeoMero are to evaluate the PK, safety and efficacy of meropenem in comparison to standard care in neonates and infants aged &lt;3 months suffering from late-onset sepsis and describe PK and safety in bacterial meningitis (BM). To achieve these aims, clinical trials on meropenem use for late-onset sepsis and BM will be developed. Using previously published PK models, a sampling scheme will be designed and population PK analysis used to identify relevant PK parameters. Safety will be evaluated through analysis of haematological and biochemical parameters and monitoring adverse events. Appearance of resistant bacteria will be monitored through regular cultures during therapy. Clinical assessments including neurological and developmental evaluations (Bayley Scales) will be conducted during two years after enrolment. Immunologic and genetic studies will also be performed to evaluate predictors of susceptibility to infections and response to therapy. In addition, resistant bacterial isolates will be studied to elucidate the mechanism of resistance and sensitive PCR assays will be used to test culture negative samples. A Paediatric Investigators Plan will be developed and submitted to the EMEA. The results of this study will then be used to develop a PUMA.

Keywords: meropenem,neonatal sepsis,neonatal meningitis,clinical trial,off label use,emea priority list,antibiotics
Improving health services for European citizens with dementia: Development of best practice strategies for the transition from ambulatory to institutional long-term care facilities (RIGHTTIMEPLACECARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Netherlands,Sweden,United Kingdom,Finland,Estonia,France,Spain
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2013-09-30
Duration (months): 45.0
Total project cost (EUR): 3897650.0
EU funding (EUR): 2982797.5
Participants: 8
Project status: CLOSED

Given the increasing number of patients/consumers with dementia, political action is urgently required to prepare the health care services throughout Europe to deliver cost effective high quality long-term care to people concerned. Currently there is a lack of clinical research data of patients/consumers and informal caregivers to develop best practice strategies for long-term care. RightTimePlaceCare intends to deliver best practice strategies for need-tailored dementia care throughout the dementia care sectors and aims to preserve best available health outcomes for both patients/consumers with dementia and their informal caregivers at affordable cost-benefit ratios. RightTimePlaceCare will describe and analyse the European health, social care and welfare systems, advocacy and informal caregiver support systems for patients/consumers with dementia and intersectorial communication. A European survey will assess the factors influencing the time of admission to institutional long-term nursing care facilities, investigate living conditions and gather clinical data of patients/consumers with dementia and their informal caregivers in long-term formal professional home care and institutional nursing care facilities, and the related economic impact. Consecutively best practice strategies will be developed for intersectorial arrangements needed to improve the effectiveness and efficiency of integrated health care in European dementia care systems, and recommendations for best practice models or interventions in long-term care facilities. RightTimePlaceCare will advance the state of the art in health systems research in dementia care and will improve cooperation between researchers to promote integration and excellence of European dementia care research. The knowledge generated by RightTimePlaceCare will empower the policy and decision makers to manage and reform dementia health care systems in view of common challenges and within the common framework of the EU.

Keywords: dementia,ambulatory care,residential facilities,delivery of health care,caregivers,cost-benefit-analysis
Living Organ Donation in Europe (LIVING DONATION)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Netherlands,Netherlands,Sweden,Germany,Belgium,Hungary,Estonia,Bulgaria,Moldova, Republic of,Romania,Poland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2012-09-30
Duration (months): 30.0
Total project cost (EUR): 1250335.4
EU funding (EUR): 1099657.0
Participants: 11
Project status: CLOSED

The project on living organ donation in Europe is a coordination action that aims to 1) establish an inventory of living donation practices in Europe, 2) explore and promote living donation as a way to increase organ availability and 3) develop tools that improve the quality and safety of living organ donations in Europe. This action aims to achieve broad European coverage with a specific focus on new EU Member States. It includes 11 participants from 10 countries. It draws upon the support, knowledge and network of the European platform on Ethical, Legal and Psychosocial Aspects of Organ Transplantation (ELPAT) and the European Society for Organ Transplantation (ESOT). To fulfil its objective this project contains 2 scientific research packages. The first package focuses on living unrelated donation practices in Europe. The second package focuses on legal restrictions and safeguards for living donations in Europe. The remaining three work packages focus on the coordination of the work, dissemination of the project results and the organisation of meetings. 13 deliverables will result from this project, including an implementation plan to guarantee European-level dissemination of the accumulated knowledge, information and recommendations. By doing so, the end-goal is to exchange best practise and effective organisational models to promote and safeguard living donation in Europe.

Keywords: ethical,legal,and psychosocial aspects of organ transplantation,exchange of best practices,living organ donation,organisational models of organ donation and transplantation
European Collaboration for Healthcare Optimization (ECHO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Spain,Slovenia,United Kingdom,Austria,Denmark,Portugal,Ireland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2014-02-28
Duration (months): 48.0
Total project cost (EUR): 3404816.2
EU funding (EUR): 2737998.0
Participants: 8
Project status: CLOSED

ECHO, European Collaboration for Healthcare Optimization, gathers the interests for Healthcare Performance Measurement of different Academic and Research Institutions from six European countries and an International Body for Healthcare Policy Analysis. Designed as a 48 months project, it has been conceived as a “pilot study” based on available administrative databases. It aims at describing the actual performance of six different Healthcare Systems at hospital, healthcare area, regional and country level. To tackle performance measurement in this project, two different methodological approaches will be used: [a] a population geographical-based, responding the question: Is the access to a diagnostic or surgical procedure dependant on the place where a person lives? And, [b] a provider-specific, answering the question: Is the risk for a patient to access high quality care -and have better health outcomes- different regarding the provider in which he or she is admitted? Utilization, equity in access and allocative efficiency will be analysed as performance measures in the former approach; and, healthcare outcomes and associated costs will be measures in the latter one. ECHO has been envisaged as a five work packages project. The first two work packages are devoted to prepare the core work package (WP#3) Performance Measurement and Report; so, the WP#1 is committed with the creation of the ECHO Data Warehouse and the second one is dedicated to the Methodological foundations of the project. Work packages #4 (web-based tools development) and #5 (dissemination) are carefully thought to ease the diffusion of our findings to decision-makers; in the former, a web-based analytical tool will allow advanced users to replicate methods and analysis; in the latter, local key agents like policy decision-makers and managers, will feed the findings making them transferable to their own decision-making process.

Keywords: healthcare performance measurement,healthcare quality,healthcare quality indicators,healthcare outcomes,healthcare utilization,equity in healthcare,heathcare efficiency,geographical analysis
European Consortium in Healthcare Outcomes and cost-benefit research (ECHOUTCOME)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: France,Italy,Belgium,France,United States,Switzerland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2013-01-31
Duration (months): 36.0
Total project cost (EUR): 1386984.2
EU funding (EUR): 1064143.0
Participants: 8
Project status: CLOSED

ECHOUTCOME is an interdisciplinary European research platform with the aim of assessing methodological properties of Healthcare Outcome and Cost-Benefit studies. The ECHOUTCOME consortium is composed by eight partners from 4 countries including three academic international experts in Outcome Research from, the French Scientific Society in Health Economics, the European office of one Multinational BioPharma industry, two research organisations (SME) specialized in advanced statistics and modelling and one organization specialized in international research administration. The general objective of this consortium is to study European health systems in order to assess decision making criteria in the frame of national needs and expectations across member states concerning healthcare outcomes and cost-benefit analyses Using both the descriptive and the experimental approaches, the ECHOUTCOME consortium will be able to investigate the relationship between quality of care with costs, efficiency and accessibility by indentifying and assessing existing approaches, but with the capability to develop new approaches for Decision Making purpose. Considering the fact that some Health agencies in Europe such as the National Institute of Clinical Excellence in the UK has published a guidance recommending one specific outcome (Quality Adjusted Life Years) and one specific Cost Benefit approach (Cost per Quality Adjusted Life Years) as a requirement for population access to innovative health technologies, it is urgent that the European Union considers the properties and consequences to use one reference case, before spreading or recommending any specific approach in other member states. ECHOUTCOME will allow to make major advancements to improve the knowledge about Health Systems organizations and expectations, existing Health Outcomes and Cost-Benefit approaches and to develop new approaches for Health decision making.

Keywords: health outcome research,cost benefit,cost utility,efficiency,acceptability
Effective Environmental Strategies for the Prevention of Alcohol Abuse among Adolescents in Europe (AAA-PREVENT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Czechia,Estonia,Germany,Italy,Belgium,Germany,Netherlands
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2013-03-31
Duration (months): 39.0
Total project cost (EUR): 2025955.2
EU funding (EUR): 1601589.0
Participants: 7
Project status: CLOSED

The consumption of alcohol among young people in Europe is rising the last years. Several studies indicate that one quarter to one third of all the students has been drinking alcohol during the last month. Also the problematic drinking is a growing issue. Especially in the age group 12 until 14 year the use of alcohol has increased the last decade. The proposed multilevel research project aims to study the different possible effective strategies for the prevention of alcohol abuse among adolescents in different European countries. It will therefore analyse existing environmental strategies of public and private actors at different governance levels and confront these with outcomes of a study to identify and analyse risk factors that influence the initiation of alcohol use among young people in Europe. The study will build upon a unique dataset from a previous survey of self reported delinquency among 74,000 young people in 33 countries, realised with active involvement of the same research consortium. The (intermediate) outcomes of the study will be largely disseminated through experts and stakeholders conferences in different European regions and a web-based prevention policy guidance book

Keywords: alcohol prevention policy,adolescents,alcohol use,initiation of alcohol,effective strategies
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Italy,France,Greece,United Kingdom,Netherlands,Poland,Germany,Norway,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2015-03-31
Duration (months): 60.0
Total project cost (EUR): 15618635.2
EU funding (EUR): 11894287.4
Participants: 11
Project status: CLOSED

Heart failure is common in Europe and its prevalence is increasing as our population ages. Despite major improvements in care since the early 90s, it is still related to a poor prognosis, an impaired quality of life and high health care costs. Many new therapies have failed to improve outcome further. One obvious reason is that the response to treatment is not homogenous. Treatment may need to be tailored to the individual patient. BIOSTAT-CHF aims to identify patients with a poor outcome, despite currently recommended therapy using information on demographics, gender, existing biomarkers, genetics and proteomics. Both genomic and proteomic analyses recently underwent major technical improvements, resulting in genome-wide analyses and detection of low abundance proteins. In BIOSTAT-CHF an index cohort of 2500 patients hospitalized with acute decompensated heart failure, will be recruited after initial stabilization. Treatment will be optimized according to the heart failure guidelines of the European Society of Cardiology with diuretics, ACE-inhibitors, betablockers and aldosterone antagonists. When patients are optimally treated, any change in symptoms and exercise tolerance will be evaluated. Patients will then be followed up for a mean of 18 months, and mortality and heart failure hospitalizations will be recorded. By using a systems biology approach, incorporating information from demographic, biomarker, genomic, proteomic, and the initial response to therapy, a risk prediction model will be designed, identifying patients with a poor outcome on currently recommended therapy. This model will then be validated in a real-life cohort of 2500 chronic heart failure patients. BIOSTAT-CHF will therefore be a major step towards personalized medicine. Identifying patients with a poor outcome on currently recommended therapy might lead to further development of targeted therapies, eventually leading to improvements in outcome for patients with heart failure in Europe

Keywords: heart failure,systems biology
Ground Deformations Risk Scenarios: an Advanced Assessment Service (DORIS)

Framework: FP7 — Cooperation
Programme: Space
Destination: Space-based applications at the service of the European Society
Action type: Collaborative project
Countries involved: Italy,Spain,Switzerland,Spain,Germany,Poland,Hungary,Italy,Netherlands
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-10-01
End date: 2013-09-30
Duration (months): 36.0
Total project cost (EUR): 4710404.12
EU funding (EUR): 3395865.98
Participants: 14
Project status: CLOSED

DORIS is an advanced downstream service for the detection, mapping, monitoring and forecasting of ground deformations, that integrates traditional and innovative Earth Observation (EO) and ground based (non-EO) data and technologies. The service delivers innovative products tailored for Civil Defense authorities. DORIS integrates state-of-the-art technological and scientific capabilities with existing European upstream services, complies with guidelines provided by the Emergency Response Core Services Interdisciplinary Group, and is linked to existing Core Services, including SAFER and GMES EMERGENCY. DORIS goes beyond the state-of-the-art technologies used to detect, map, monitor and forecast ground deformations. DORIS uses the unique ERS-1/2 and ENVISAT C-band SAR archives to provide unprecedented, very long time-series of ground deformations. DORIS evaluates new SAR sensors, including ALOS, COSMO-SkyMed and TERRASAR-X, exploiting the different bands (L/X), the significantly reduced revisiting time, and the higher spatial resolution offered by these sensors. DORIS moves forward the integration of satellite and ground-based SAR interferometry, coupled with GPS measurements and geophysical probing. DORIS exploits multi-spectral images to map ground deformations, to identify the elements at risk, and for dynamic risk scenarios design. Finally, DORIS investigates the possibility of using thermal images for the assessment of landslide susceptibility and hazard. DORIS will be tested in six study areas in Europe. Successful application of the service in these areas guarantees that the downstream service will work in Europe. DORIS will provide a business model for long term self-sustainability of the service; the project is proposed by a unique team of public administrations, research institutes, and enterprises with experience in EO technologies for Civil Defence applications. DORIS favors knowledge and technology transfer, and will stimulate European competitiveness.

Keywords: ground deformations,eo technologies,downstream service